The decision above the decision —
which AI, clinical and program investments to make, and in what order.
Payers and health systems are pouring capital into operational AI — prior authorization, ambient documentation, payment integrity, care management. The harder, higher-value question is which of those investments to fund, in what sequence, with what business case. Prioriti AI governs that decision — multi-lens, board-ready, and auditable — so the money you spend on healthcare AI actually delivers against its committed outcomes.
A large payer or health system will have 500 AI, clinical and digital initiatives that each look attractive — and the budget and clinical-informatics bandwidth for perhaps 50. Which ones, in what order, and how much to spend is the decision that separates the winners. Prioriti AI is the strategic layer that makes those calls accurate, defensible, and governed — the intelligence that determines where healthcare AI actually pays off.
Healthcare leads every industry in AI pilots — and trails in value realized
The gap isn't the AI. Payers and systems can buy world-class ambient documentation, imaging triage, payment-integrity and care-management models. The gap is upstream: deciding which of those investments to fund, in what sequence, and proving the business case — a decision made today by committee, politics, and spreadsheets.
Piloting AI
~80% of health systems and payers are piloting or deploying AI — but value realization consistently lags adoption. The bottleneck is governance, not technology.
Decided by feel
$50–300M in annual clinical, digital and AI investment is allocated through hierarchy and political weight, not structured strategic decisioning.
Cycle at stake
A wrong prioritization at concept stage wastes 12–18 months of clinical-informatics and IT investment before anyone knows it was wrong.
Governance is the #1 barrier
Surveys name governance — not model quality — as the primary barrier to scaling AI. CMS, OCR and state regulators now require documented decision governance.
Adoption is ahead of value
Directional, per HIMSS & Deloitte health-AI surveys (2025) and Grant Thornton 2026 AI Impact Survey.
Where strategic value leaks
Illustrative decomposition of investment-to-outcome loss.
Above the operational AI — not competing with it
Epic and the EHR AI suites, ambient-documentation vendors, payment-integrity and care-management platforms are winning the operational layer with real production results. Prioriti AI is the layer above: the decision about which of those investments to make, in what sequence, with what business case. Click a layer to see who does what.
Pick your segment. Pick a decision. Watch the outcome take shape.
Payers, health systems and pharmacy don't share one pain profile — different regulators, timeframes, and clinical stakes. Choose a segment, click a strategic decision, and the chain and spider chart show the lift Prioriti AI targets.
From competing alternatives to a governed, board-ready decision
Hover the flow or tap a stage. Decision velocity here is the speed from a pile of competing investment proposals to a sequenced, defensible decision — with the rationale documented for the CFO and the regulator.
Alternatives In
- Competing clinical, program & AI initiatives
- Investment cases & portfolio spend
- CMS, HIPAA & state constraints
- Clinical, actuarial & market signals
Prioriti AI Reasons
- Score & rank across multiple lenses
- Sequence for momentum & dependency
- Apply regulatory governance lenses
- Human-in-the-loop approval gates
Governed Decision
- Board-ready business case
- Capital reallocated to higher return
- Sequenced investment roadmap
- Deterministic, auditable rationale
The dimensions where operational AI — and the spreadsheet — can't play
Operational AI executes decisions; it doesn't govern which to make. Committees govern, but without rigor or an audit trail. Here's how Prioriti AI compares on the dimensions that decide capital.
Model your reallocation upside
Slide in your portfolio's scale and how it's decided today, then pick a scenario. We break the upside into named levers as a percentage of the portfolio you already fund — anchored to your book, not a single absolute number, and bookended conservative-to-aggressive. Illustrative, not a quote.
Your investment portfolio, roughly
Three levels of value, mapped to how payers and systems decide
We don't sell AI as a capability. We sell better strategic decisions — measured against the capital you already allocate.
Capital reallocated to higher return
We anchor to the portfolio you already fund and frame value in your units — a 5% improvement on a $50M portfolio is $2.5M; 40% is $20M. The upside scales with your book, and ROI is legible before signature.
Decision velocity, without losing rigor
Compress an 8-week prioritization to days — parallel multi-lens review instead of sequential, siloed sign-offs — so 18–24 month product cycles stop waiting on one contested call.
Governed decisions that clear the bar
Every recommendation is versioned, confidence-scored, and audit-ready, with human-in-the-loop as the final gate — aligned to CMS AI guidance, HIPAA and OCR rules, state PA statutes, ONC algorithm-transparency requirements, and the EU AI Act. The reason healthcare AI fails becomes your switching cost.
Human-augmented, not autonomous — because healthcare requires it
Agents continuously scan your market, portfolio, and risk environment, surfacing decisions for human review before they become urgent. Human oversight isn't an afterthought; it is the design. That is what the regulators now require — and documenting it is a differentiator today, hygiene tomorrow.
Healthcare regulatory lens library
CMS and state PA statutes, HIPAA and OCR guidance, FDA SaMD pathways, ONC algorithm-transparency rules, EU AI Act high-risk classification — scored as decision inputs, not bolted on after.
Deterministic audit trail
Every recommendation is versioned and confidence-scored, with the full rationale and every human action recorded — ready for CMS audit and model-risk review.
Human-in-the-loop gates
Approval gates on every consequential decision. Iowa's 2026 AI-denial ban, CMS review rules, and the EU AI Act expect it — Prioriti AI is built for oversight, not around it.
Vendor-neutral by design
Prioriti AI governs which operational AI to fund and how much — optimized for your interests, not the vendor whose funding it's deciding. Whose interests should govern that call?
“How does Prioriti AI relate to Epic and the ambient-AI vendors?” They're complementary. They execute the operational investment; Prioriti AI governs the strategic decision that determines which investments to make, in what sequence, with what business case — in your interest, not the vendor's.
Pick a role. See the decision it sharpens.
The value lands differently for each executive who owns a piece of the strategic investment call.
Advisory first, platform next — value compounds
We're honest about where the product is today. The engagement starts as an outcome-measured advisory partnership, accumulates your decision data, and matures into the platform — each phase raising decision velocity across more of the book.
Land a real decision (Design Partner)
A live, high-stakes investment call — a Stars investment, a PA-governance call, an ambient-AI rollout — decided with Prioriti AI's framework and measured against your own baseline.
Prove the committed outcome
A time-boxed engagement producing reference metrics in your units: cycle time cut, capital reallocated, compliance risk reduced — documented and defensible.
Adopt the platform
Your decisions and lenses move onto Prioriti AI — each governed call accumulating the data that makes the platform harder to replace.
Scale across the enterprise
Extend governed decision-making across plans, regions and service lines — from clinical AI strategy to enterprise capital allocation.
Help shape the future of healthcare decision governance
The Design Partner Program is for payers, health systems and PBMs that want to be at the frontier of AI investment governance — a collaborative, outcome-measured engagement at a preferred investment.
Design Partners get
A full advisory engagement, plus a seat at the table as the platform is built.
- Priority access to new decision lensesHealthcare-specific lenses as they're built — CMS & quality, clinical value, network & pharmacy.
- Co-authorship on published benchmarksYour anonymized outcomes shape the reference metrics the market cites.
- Direct input into the roadmapFirst right of refusal on expanded capabilities before general availability.
- Preferred investmentAdvisory-grade engagement at Design Partner economics.
Design Partners commit to
A genuine partnership — the mechanism for building the reference the whole market will look to.
- A 6–12 month engagementCollaborative, with quarterly framework review sessions.
- Anonymized outcome dataShared for benchmark development, scope agreed in advance.
- Reference availabilityWillingness to say publicly: “PAI helped us make a better decision.”
The Full Strategic Decisioning Suite
Twenty-five integrated components spanning strategic analysis, prioritization, financial analysis, and portfolio management — all designed to govern the decisions that determine where your AI and product investments pay off.
Bring us your next big investment decision
A Stars investment, a PA-governance call, an ambient-AI rollout, or a $50M clinical AI roadmap. We'll run it through Prioriti AI's framework and show you a governed, board-ready decision — measured in your own units.
Prioriti AI is built for the executives who decide where healthcare capital goes — Chief Medical Officer, CMIO, VP Medical Management, Chief Strategy Officer, and CFO — who need faster, more objective, and more accountable investment decisions.
